Compare BWEN & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWEN | BMEA |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.8M | 95.4M |
| IPO Year | 2009 | 2021 |
| Metric | BWEN | BMEA |
|---|---|---|
| Price | $4.34 | $1.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $6.00 | ★ $9.83 |
| AVG Volume (30 Days) | 478.3K | ★ 920.2K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 360.00 | 69.19 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $146,785,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.84 | $0.87 |
| 52 Week High | $5.40 | $2.99 |
| Indicator | BWEN | BMEA |
|---|---|---|
| Relative Strength Index (RSI) | 50.41 | 47.90 |
| Support Level | $4.10 | $1.23 |
| Resistance Level | $4.90 | $1.46 |
| Average True Range (ATR) | 0.45 | 0.10 |
| MACD | -0.09 | 0.02 |
| Stochastic Oscillator | 25.67 | 40.00 |
Broadwind Inc is a precision manufacturer of structures, equipment, and components for clean technology and other specialized applications. The company provides technologically high-value products to customers with complex systems and stringent quality standards that operate in the energy, mining, and infrastructure sectors in the United States of America. Its capabilities include heavy fabrications, welding, metal rolling, coatings, gear cutting and shaping, gearbox manufacturing and repair, heat treatment, CNG decompression, precision machining, assembly, engineering, and packaging solutions, among others. The company operates in four reportable segments: Heavy Fabrications, which generates the maximum revenue, Gearing, Industrial Solutions, and Corporate.
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.